TIDMVRP 
 
Verona Pharma plc 
 
("Verona Pharma" or the "Company") 
 
  Secondary listing to provide trading facility on Xetra Exchange in Germany 
 
12 June 2015, Cardiff - Verona Pharma plc ('Verona' or 'the Company'), the AIM 
listed drug development company focused on first-in-class medicines to treat 
respiratory diseases, announces today it has undertaken a secondary listing on 
the Xetra exchange, part of the Deutsche Borse in Germany. The German cusip is 
ISIN: GB00B06GSH43 and the symbol is I9S. 
 
Verona Pharma has engaged Oddo Seydler AG to act as designated sponsor and 
market maker for the company's shares on the Frankfurt exchange and the 
electronic Xetra platform. The Company has chosen to list on the Xetra exchange 
as a way of further raising its profile within continental Europe and to 
increase the potential for investors in German-speaking Europe to trade in the 
Company's shares. 
 
-Ends- 
 
For further information please contact: 
 
Verona Pharma plc                      Tel: +44 (0) 20 7863 3300 
 
Jan-Anders Karlsson, CEO 
 
N+1 Singer                             Tel: +44 (0)20 7496 3000 
 
Aubrey Powell / Jen Boorer 
 
FTI Consulting                         Tel: +44 (0)20 3727 1000 
 
Julia Phillips / Simon Conway 
 
Notes to Editors 
 
About Verona Pharma plc 
 
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company 
focused on the development of innovative prescription medicines to treat 
respiratory diseases with significant unmet medical needs, such as chronic 
obstructive pulmonary disease (COPD), asthma and cystic fibrosis. 
 
Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase 
2 trials as a nebulised treatment for acute exacerbations of COPD in the 
hospital setting.  The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and 
therefore has both bronchodilator and anti-inflammatory effects, which are 
essential to the improvement of patients with COPD and asthma. 
 
Verona Pharma is also building a broader portfolio of RPL554-containing 
products to maximise its benefit to patients and its value.  This includes the 
very significant markets for COPD and asthma maintenance therapy.  The Company 
is also exploring the potential of the drug in different diseases, such as 
cystic fibrosis, where it is in pre-clinical testing and has recently received 
a Venture and Innovation Award from the UK Cystic Fibrosis Trust. 
 
 
 
END
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Verona Pharma Charts.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Verona Pharma Charts.